Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrasonographic changes in median nerve cross-sectional area in the elderly: effects of aging and type 2 diabetes.

BMC geriatrics·2025
Same author

Long COVID-19: a Four-Year prospective cohort study of risk factors, recovery, and quality of life.

BMC infectious diseases·2025
Same author

The incidence, clinical features and outcome of urinary tract infections in geriatric patients: A prospective longitudinal study.

IJID regions·2024
Same author

The Outcome of BNT162b2, ChAdOx1-Sand mRNA-1273 Vaccines and Two Boosters: A Prospective Longitudinal Real-World Study.

Viruses·2023
Same author

Application of Mathematical Modeling in Prediction of COVID-19 Transmission Dynamics.

Arabian journal for science and engineering·2022
Same author

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents.

Hepatic medicine : evidence and research·2014

Related Experiment Video

Updated: Jun 5, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Hepatitis C virus genotype 4 therapy: progress and challenges.

Sanaa M Kamal1

  • 1Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, Cairo, Egypt. sanaa.kamal@link.net

Liver International : Official Journal of the International Association for the Study of the Liver
|January 6, 2011
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus genotype 4 (HCV-4) treatment has improved with pegylated interferons and ribavirin, offering higher sustained virological response rates. Further research is needed for challenging patient groups and emerging therapies.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Experiment Videos

Last Updated: Jun 5, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus genotype 4 (HCV-4) is prevalent in Egypt, the Middle East, and Africa.
  • HCV-4 epidemiology is shifting, with increased spread to Europe via immigration and injection drug use.
  • HCV-4 has historically been difficult to treat, yielding low sustained virological response (SVR) rates with interferon-based regimens.

Purpose of the Study:

  • To review the current treatment landscape for HCV genotype 4.
  • To highlight recent advancements and persistent challenges in managing HCV-4 infections.
  • To emphasize the need for further research and inclusion of HCV-4 patients in clinical trials.

Main Methods:

  • Review of existing literature on HCV genotype 4 treatment.
  • Analysis of sustained virological response (SVR) rates with different therapeutic regimens.
  • Identification of patient subgroups posing therapeutic challenges.

Main Results:

  • Pegylated interferons plus ribavirin therapy increased SVR rates to over 60% for chronic HCV-4.
  • Shorter treatment durations for patients with rapid virological response improved outcomes and compliance.
  • Significant therapeutic challenges remain for non-responders, injection drug users, HIV-coinfected, thalassaemic, and haemodialysis patients, and post-transplant recurrence cases.

Conclusions:

  • HCV-4 treatment has significantly improved, with higher SVR rates and shorter regimens.
  • Despite progress, specific patient populations require optimized therapeutic strategies.
  • Further research and inclusion in clinical trials for novel therapies are crucial for advancing HCV-4 management.